Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration

Autores
Dardiotis, Efthimios; Panayiotou, Elena; Feldman, Mariana Laura; Hadjisavvas, Andreas; Malas, Stavros; Vonta, Ilia; Hadjigeorgiou, Georgios; Kyriakou, Kyriakos; Kyriakides, Theodoros
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
In amyotrophic lateral sclerosis (ALS) reactive oxygen species and apoptosis are implicated in disease pathogenesis. Melatonin with its anti-oxidant and anti-apoptotic properties is expected to ameliorate disease phenotype. The aim of this study was to assess possible neuroprotection of melatonin in the G93A-copper/zinc superoxide dismutase (G93ASOD1) transgenic mouse model of ALS. Four groups of mice, 14 animals each, were injected intraperitoneally with 0 mg/kg, 0.5 mg/kg, 2.5 mg/kg and 50 mg/kg of melatonin from age 40 days. The primary end points were; disease onset, disease duration, survival and rotarod performance. No statistically significant difference in disease onset between the four groups was found. Survival was significantly reduced with the 0.5 mg/kg and 50 mg/kg doses and tended to be reduced with the 2.5 mg/kg dose. Histological analysis of spinal cords revealed increased motoneuron loss in melatonin treated mice. Melatonin treated animals were associated with increased oxidative stress as assessed with 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation. Histochemistry and Western blot data of spinal cord from melatonin treated mice revealed upregulation of human SOD1 compared to untreated mice. In addition, real-time PCR revealed a dose dependent upregulation of human SOD1 in melatonin treated animals. Thus, intraperitoneal melatonin, at the doses used, does not ameliorate and perhaps exacerbates phenotype in the G93ASOD1 mouse ALS model. This is probably due to melatonin's effect on upregulating gene expression of human toxic SOD1. This action presumably overrides any of its direct anti-oxidant and anti-apoptotic properties.
Fil: Dardiotis, Efthimios . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Panayiotou, Elena . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Feldman, Mariana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas; Argentina
Fil: Hadjisavvas, Andreas . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Malas, Stavros . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Vonta, Ilia. National Technical University of Athens; Grecia
Fil: Hadjigeorgiou, Georgios . Centre for Research and Technology-Thessaly; Grecia
Fil: Kyriakou, Kyriakos . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Kyriakides, Theodoros . The Cyprus Institute of Neurology and Genetics; Chipre
Materia
Amyotrophic Lateral Sclerosis
G93asod1 Transgenic Mouse Model
Melatonin
Neuroprotection
Oxidative Stress
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/13048

id CONICETDig_e30371608b478e0d6ad1a3881b29e16d
oai_identifier_str oai:ri.conicet.gov.ar:11336/13048
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegenerationDardiotis, Efthimios Panayiotou, Elena Feldman, Mariana LauraHadjisavvas, Andreas Malas, Stavros Vonta, IliaHadjigeorgiou, Georgios Kyriakou, Kyriakos Kyriakides, Theodoros Amyotrophic Lateral SclerosisG93asod1 Transgenic Mouse ModelMelatoninNeuroprotectionOxidative Stresshttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1In amyotrophic lateral sclerosis (ALS) reactive oxygen species and apoptosis are implicated in disease pathogenesis. Melatonin with its anti-oxidant and anti-apoptotic properties is expected to ameliorate disease phenotype. The aim of this study was to assess possible neuroprotection of melatonin in the G93A-copper/zinc superoxide dismutase (G93ASOD1) transgenic mouse model of ALS. Four groups of mice, 14 animals each, were injected intraperitoneally with 0 mg/kg, 0.5 mg/kg, 2.5 mg/kg and 50 mg/kg of melatonin from age 40 days. The primary end points were; disease onset, disease duration, survival and rotarod performance. No statistically significant difference in disease onset between the four groups was found. Survival was significantly reduced with the 0.5 mg/kg and 50 mg/kg doses and tended to be reduced with the 2.5 mg/kg dose. Histological analysis of spinal cords revealed increased motoneuron loss in melatonin treated mice. Melatonin treated animals were associated with increased oxidative stress as assessed with 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation. Histochemistry and Western blot data of spinal cord from melatonin treated mice revealed upregulation of human SOD1 compared to untreated mice. In addition, real-time PCR revealed a dose dependent upregulation of human SOD1 in melatonin treated animals. Thus, intraperitoneal melatonin, at the doses used, does not ameliorate and perhaps exacerbates phenotype in the G93ASOD1 mouse ALS model. This is probably due to melatonin's effect on upregulating gene expression of human toxic SOD1. This action presumably overrides any of its direct anti-oxidant and anti-apoptotic properties.Fil: Dardiotis, Efthimios . The Cyprus Institute of Neurology and Genetics; ChipreFil: Panayiotou, Elena . The Cyprus Institute of Neurology and Genetics; ChipreFil: Feldman, Mariana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas; ArgentinaFil: Hadjisavvas, Andreas . The Cyprus Institute of Neurology and Genetics; ChipreFil: Malas, Stavros . The Cyprus Institute of Neurology and Genetics; ChipreFil: Vonta, Ilia. National Technical University of Athens; GreciaFil: Hadjigeorgiou, Georgios . Centre for Research and Technology-Thessaly; GreciaFil: Kyriakou, Kyriakos . The Cyprus Institute of Neurology and Genetics; ChipreFil: Kyriakides, Theodoros . The Cyprus Institute of Neurology and Genetics; ChipreElsevier Ireland2013-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/13048Dardiotis, Efthimios ; Panayiotou, Elena ; Feldman, Mariana Laura; Hadjisavvas, Andreas ; Malas, Stavros ; et al.; Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration; Elsevier Ireland; Neuroscience Letters; 548; 8-2013; 170-1750304-3940enginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0304394013005053info:eu-repo/semantics/altIdentifier/doi/10.1016/j.neulet.2013.05.058info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:55:29Zoai:ri.conicet.gov.ar:11336/13048instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:55:29.841CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration
title Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration
spellingShingle Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration
Dardiotis, Efthimios
Amyotrophic Lateral Sclerosis
G93asod1 Transgenic Mouse Model
Melatonin
Neuroprotection
Oxidative Stress
title_short Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration
title_full Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration
title_fullStr Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration
title_full_unstemmed Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration
title_sort Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration
dc.creator.none.fl_str_mv Dardiotis, Efthimios
Panayiotou, Elena
Feldman, Mariana Laura
Hadjisavvas, Andreas
Malas, Stavros
Vonta, Ilia
Hadjigeorgiou, Georgios
Kyriakou, Kyriakos
Kyriakides, Theodoros
author Dardiotis, Efthimios
author_facet Dardiotis, Efthimios
Panayiotou, Elena
Feldman, Mariana Laura
Hadjisavvas, Andreas
Malas, Stavros
Vonta, Ilia
Hadjigeorgiou, Georgios
Kyriakou, Kyriakos
Kyriakides, Theodoros
author_role author
author2 Panayiotou, Elena
Feldman, Mariana Laura
Hadjisavvas, Andreas
Malas, Stavros
Vonta, Ilia
Hadjigeorgiou, Georgios
Kyriakou, Kyriakos
Kyriakides, Theodoros
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Amyotrophic Lateral Sclerosis
G93asod1 Transgenic Mouse Model
Melatonin
Neuroprotection
Oxidative Stress
topic Amyotrophic Lateral Sclerosis
G93asod1 Transgenic Mouse Model
Melatonin
Neuroprotection
Oxidative Stress
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv In amyotrophic lateral sclerosis (ALS) reactive oxygen species and apoptosis are implicated in disease pathogenesis. Melatonin with its anti-oxidant and anti-apoptotic properties is expected to ameliorate disease phenotype. The aim of this study was to assess possible neuroprotection of melatonin in the G93A-copper/zinc superoxide dismutase (G93ASOD1) transgenic mouse model of ALS. Four groups of mice, 14 animals each, were injected intraperitoneally with 0 mg/kg, 0.5 mg/kg, 2.5 mg/kg and 50 mg/kg of melatonin from age 40 days. The primary end points were; disease onset, disease duration, survival and rotarod performance. No statistically significant difference in disease onset between the four groups was found. Survival was significantly reduced with the 0.5 mg/kg and 50 mg/kg doses and tended to be reduced with the 2.5 mg/kg dose. Histological analysis of spinal cords revealed increased motoneuron loss in melatonin treated mice. Melatonin treated animals were associated with increased oxidative stress as assessed with 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation. Histochemistry and Western blot data of spinal cord from melatonin treated mice revealed upregulation of human SOD1 compared to untreated mice. In addition, real-time PCR revealed a dose dependent upregulation of human SOD1 in melatonin treated animals. Thus, intraperitoneal melatonin, at the doses used, does not ameliorate and perhaps exacerbates phenotype in the G93ASOD1 mouse ALS model. This is probably due to melatonin's effect on upregulating gene expression of human toxic SOD1. This action presumably overrides any of its direct anti-oxidant and anti-apoptotic properties.
Fil: Dardiotis, Efthimios . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Panayiotou, Elena . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Feldman, Mariana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas; Argentina
Fil: Hadjisavvas, Andreas . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Malas, Stavros . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Vonta, Ilia. National Technical University of Athens; Grecia
Fil: Hadjigeorgiou, Georgios . Centre for Research and Technology-Thessaly; Grecia
Fil: Kyriakou, Kyriakos . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Kyriakides, Theodoros . The Cyprus Institute of Neurology and Genetics; Chipre
description In amyotrophic lateral sclerosis (ALS) reactive oxygen species and apoptosis are implicated in disease pathogenesis. Melatonin with its anti-oxidant and anti-apoptotic properties is expected to ameliorate disease phenotype. The aim of this study was to assess possible neuroprotection of melatonin in the G93A-copper/zinc superoxide dismutase (G93ASOD1) transgenic mouse model of ALS. Four groups of mice, 14 animals each, were injected intraperitoneally with 0 mg/kg, 0.5 mg/kg, 2.5 mg/kg and 50 mg/kg of melatonin from age 40 days. The primary end points were; disease onset, disease duration, survival and rotarod performance. No statistically significant difference in disease onset between the four groups was found. Survival was significantly reduced with the 0.5 mg/kg and 50 mg/kg doses and tended to be reduced with the 2.5 mg/kg dose. Histological analysis of spinal cords revealed increased motoneuron loss in melatonin treated mice. Melatonin treated animals were associated with increased oxidative stress as assessed with 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation. Histochemistry and Western blot data of spinal cord from melatonin treated mice revealed upregulation of human SOD1 compared to untreated mice. In addition, real-time PCR revealed a dose dependent upregulation of human SOD1 in melatonin treated animals. Thus, intraperitoneal melatonin, at the doses used, does not ameliorate and perhaps exacerbates phenotype in the G93ASOD1 mouse ALS model. This is probably due to melatonin's effect on upregulating gene expression of human toxic SOD1. This action presumably overrides any of its direct anti-oxidant and anti-apoptotic properties.
publishDate 2013
dc.date.none.fl_str_mv 2013-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/13048
Dardiotis, Efthimios ; Panayiotou, Elena ; Feldman, Mariana Laura; Hadjisavvas, Andreas ; Malas, Stavros ; et al.; Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration; Elsevier Ireland; Neuroscience Letters; 548; 8-2013; 170-175
0304-3940
url http://hdl.handle.net/11336/13048
identifier_str_mv Dardiotis, Efthimios ; Panayiotou, Elena ; Feldman, Mariana Laura; Hadjisavvas, Andreas ; Malas, Stavros ; et al.; Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration; Elsevier Ireland; Neuroscience Letters; 548; 8-2013; 170-175
0304-3940
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0304394013005053
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.neulet.2013.05.058
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Ireland
publisher.none.fl_str_mv Elsevier Ireland
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782258094014464
score 12.982451